Olakunle Akinboboye, MD
Internal Medicine · Laurelton, NYNPI 1780632844
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $255,772 of the $382,239 with a category attached, or 66.9%. Alnylam Pharmaceuticals Inc. accounts for 60.8% of it on its own, with 53 other manufacturers making up the rest. 2025 is the largest year on record at $126,477, 9.2 times the $13,787 reported in 2019. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,106 payments — averaging $345.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$232K
- Pfizer$49K
- Akcea Therapeutics, Inc.$38K
- Bridgebio Pharma, Inc.$14K
- Jazz Pharmaceuticals Inc.$13K
- AstraZeneca$12K
- plus $24K from 48 others
Across 325 payments — averaging $4141.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$395K
- Janssen Research & Development, LLC$180K
- Novartis$101K
- Pfizer$99K
- Boehringer Ingelheim Pharma GmbH & Co.kg$91K
- Astrazeneca UK Limited$87K
- plus $391K from 11 others
Across 1 payment — averaging $131,168 each. An ownership or investment interest held by the physician or an immediate family member.
- Vivaquant Inc, Dba Rhythm Express$131K
What the payments were for
- Consulting fees$71,34919%
- Speaking & faculty fees$255,77267%
- Travel & lodging$29,7868%
- Food & beverage$25,2777%
- Education$550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$382,239 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AmvuttraVutrisiran Sodium | 19 | $2,227,576 |
| VyndamaxTafamidis | 20 | $495,887 |
| OzempicSemaglutide | 208 | $254,057 |
| VyndaqelTafamidis Meglumine | 11 | $242,642 |
| FarxigaDapagliflozin Propanediol | 185 | $192,006 |
| EntrestoSacubitril/Valsartan | 140 | $162,838 |
| EliquisApixaban | 115 | $132,826 |
| MounjaroTirzepatide | 90 | $110,329 |
| JardianceEmpagliflozin | 84 | $106,358 |
| XareltoRivaroxaban | 94 | $106,168 |
| JanumetSitagliptin Phos/Metformin Hcl | 42 | $52,507 |
| JanuviaSitagliptin Phosphate | 31 | $43,812 |
| Metformin Er GastricMetformin Hcl | 13 | $33,159 |
| VerquvoVericiguat | 34 | $32,470 |
| TrulicityDulaglutide | 26 | $31,911 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alnylam Pharmaceuticals Inc.Amvuttra | $232,271 | $2,227,57619 claims |
| PfizerVyndamax, Vyndaqel, Eliquis | $49,180 | $871,355146 claims |
| Novo NordiskOzempic, Wegovy | $1,718 | $281,869228 claims |
| AstraZenecaFarxiga, Brilinta | $11,990 | $208,346204 claims |
| NovartisEntresto | $1,182 | $162,838140 claims |
| Lilly USA, LLCMounjaro, Trulicity | $738 | $142,240116 claims |
| MerckJanumet, Januvia, Verquvo | $4,129 | $128,789107 claims |
| Boehringer IngelheimJardiance | $1,171 | $106,35884 claims |
| Johnson & JohnsonXarelto | $1,396 | $106,16894 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $69 | $25,34454 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $756 | $11,73612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Laurelton
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Anthony MartinezBuffalo$1.6M
- Javier MoralesGreenvale$1.3M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.